First generation treatments for Alzheimer’s disease (AD), which act to enhance acetylcholine function by inhibiting breakdown of acetylcholine (acetlycholinesterase inhibitors, ACHE-Is), have provided mild relief of symptoms, with a good safety profile. However, there remains interest in developing drugs that are better tolerated and more effective at treating symptoms, both when administered alone and in combination with ACHE-Is. Moreover, there remains a need for new agents that slow the progression of AD. This presentation will discuss some of the opportunities and challenges in developing improved symptom-modifying agents and agents for the slowing of disease progression. Examples from recent trials with ACHE-Is and other agents will be used for illustration.
Back to S019 New Drug Development in Psychogeriatrics
Back to The Eleventh International Congress